Sharpe ratio
1.61Return earned for the risk taken.
Good
Good risk-adjusted returns. The fund has delivered strong returns for its level of risk.
+31.62%1Y Absolute Return
-0.28%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Growth Option - Direct PlanFund 3Y annualised return · 5Y history unavailable | ₹16,72,954 | ₹7,32,612 | ₹9,40,342 | +31.31% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.32
₹1 Lakh since launch₹1.32 Lakh
Fund age3.1 yrs
Fund information
Scheme code152082
ISININF179KC1HO1
BenchmarkBSE Healthcare TRI
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio1.08%
Exit loadExit load of 1%, if redeemed within 30 days.
Minimum SIP₹100 SIP
Return comparison
9th / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +234.48% | — | — |
| 3M | +26.45% | — | — |
| 6M | +40.26% | — | — |
| 1Y | +31.62% | — | +4.16% |
| 3Y | +31.31% | — | +12.54% |
| Since Launch | +31.75% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
2.36Return earned while limiting downside risk.
Excellent
Excellent downside risk-adjusted returns. The fund has managed downside risk very effectively.
Standard deviation
13.95%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
2.13How well the fund rewarded investors relative to its biggest decline.
Excellent
Excellent balance between returns and drawdowns.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 39 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 9.66% |
| Divi's Laboratories Ltd | Healthcare | Equity | 9.14% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 4.82% |
| Aster DM Healthcare Ltd | Healthcare | Equity | 4.7% |
| Lupin Ltd | Healthcare | Equity | 4.67% |
| Cipla Ltd | Healthcare | Equity | 4.64% |
| Alkem Laboratories Ltd | Healthcare | Equity | 3.67% |
| Ami Organics Ltd | Healthcare | Equity | 3.58% |
| Anthem Biosciences Ltd. | Healthcare | Equity | 3.56% |
| Neuland Laboratories Ltd | Healthcare | Equity | 3.4% |
Fund management
DH
Dhruv Muchhal
Since 2023 · Prior to joining HDFC MF,he has worked with Motilal Oswal Financial Services Ltd., Goldman Sachs, CRISIL Global Research & Analytics and Deloitte Haskins & Sells
Mr. Dhruv has done B.Com, CA and CFA
NI
Nikhil Mathur
Since 2023 · Prior to joining HDFC Mutual Fund, he has worked with Ambit Capital, Goldman Sachs, Deloitte India and EY
Mr. Mathur has done B.Tech and PGDM in Finance
Compare similar funds
No comparable category funds are available yet.
Summary
A very high-risk equity scheme - sectoral/ thematic fund. Ahead of its category average over 3Y by 18.8 points. Healthcare makes up 100% — trouble in that sector hits the whole fund.
Strengths
- Ahead of its category average over 3Y by 18.8 points.
- Losses and swings stayed contained — worst fall -14.9%, volatility 13.9%.
- Recovered from its worst fall in 4 months.
- Ranks 9 of 932 in its category over 1 year.
Weaknesses
- None
Ideal investor
- Needs a 5–7+ years horizon to ride out its very high risk level.
- Good fit for SIPs — spreading purchases smooths out 13.9% volatility.
Risk drivers
- Healthcare makes up 100% — trouble in that sector hits the whole fund.